Biofourmis raises $100 million funding led by SoftBank Vision Fund 2

Health-tech company Biofourmis on September 3 said it has raised $100 million in funding led by SoftBank Vision Fund 2. In May last year, Biofourmis closed its $35 million series B round. “COVID-19 is pushing remote monitoring and digital therapeutics to the forefront of medicine. Our vision is to use digital medicine to empower patients, clinicians and researchers everywhere by providing software-as-a-treatment for patients with unmet clinical needs, from post-acute care to optimal medication therapy,” Biofourmis CEO Kuldeep Singh Rajput said. Biofourmis will use the funding for developing, validating and commercialising several released and unreleased digital therapeutics solutions across cardiology, respiratory, oncology and pain, with a focus on the US and key Asian markets, including Asia Pacific, China and Japan, the company said. “We believe predictive health is the future of medicine and Biofourmis is a leader in using AI and machine learning-based solutions to advance digital therapeutics,” Greg Moon, Managing Partner at SoftBank Investment Advisers, said. The new business structure will include two verticals – Biofourmis Therapeutics and Biofourmis Health.